ARA-290, also called cibinetide in some secondary sources, is an 11-amino-acid peptide studied as a selective innate-repair-receptor ligand in preclinical systems. The original overview of this page asks three questions: its relationship to erythropoietin-derived sequence research, innate-repair-receptor model questions, and mass confirmation and purity reporting. The cited papers below use the names ARA-290 and pHBSP; they do not, in the records verified for this draft, use the name cibinetide.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
EPO-derived sequence and the innate repair receptor
Brines and colleagues reported that tissue-protective functions of erythropoietin (EPO) can be delimited to short peptide sequences from helix B (residues 58-82), and that an 11-amino-acid peptide composed of adjacent amino acids forming the aqueous face of helix B was tissue-protective in the models they described, without being erythropoietic in vitro or in vivo (Brines et al., 2008). They distinguished hematopoiesis, mediated by the EPO-receptor homodimer, from tissue protection mediated by a heterocomplex of the EPO receptor and CD131 (the β common receptor).
Collino, Thiemermann, Cerami, and Brines later described that heterodimer as the innate repair receptor (IRR) and identified the latest generation of selective IRR ligands as an 11-amino-acid peptide modeled from the helix-B region of EPO, called pyroglutamate helix B surface peptide (pHBSP; ARA-290) (Collino et al., 2015). ARA-290 is not recombinant EPO, and an EPO-activity file should not be borrowed for this peptide.
Published observations — and their limits
Brines and colleagues reported therapeutic benefit of the 11-amino-acid helix-B peptide in models of ischemic stroke and renal ischemia-reperfusion, and they also reported trophic effects that included accelerated wound healing and augmented cognitive function in rodents, without erythropoietic activity in the assays they used (Brines et al., 2008). Collino and colleagues reviewed longer-lasting tissue-protection and repair effects attributed to this selective IRR ligand (Collino et al., 2015). The 2015 article is a review. Neither paper is a use instruction, and neither describes a current catalog lot.
Mass confirmation and purity reporting
An 11-residue peptide still needs sequence identity, mass confirmation, purity, and lot matching. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.
ARA-290 appears in Velnacor’s research-material catalog (internal product record, slug ara290). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact name, specification, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.
Name discipline matters here. The cited papers use ARA-290 and pHBSP. The original overview of this page also uses the name cibinetide. That synonym is recorded as language from the original page, not as a word placed in the mouth of Brines or Collino. A quotation, a certificate, and a laboratory notebook should use the identifier that the supplier actually printed, and they should not borrow an EPO activity file or an erythropoietic specification for this 11-residue peptide.
Selected published literature
- Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences. 2008;105(31):10925-10930. doi:10.1073/pnas.0805594105. PubMed 18676614.
- Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacology & Therapeutics. 2015;151:32-40. doi:10.1016/j.pharmthera.2015.02.005. PubMed 25728128. Review article; cited for pHBSP/ARA-290 and innate-repair-receptor identity, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.